Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.63 |
| ▸ | POLA1 | P09884 | 2/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.44 |
| ▸ | ITGAV | P06756 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24703970 | 1.00 | PDE3A (0.63) | PDE3APDE4DSLC29A1POLA1ITGB3 | |
| SCHEMBL24703971 | 1.00 | PDE3A (0.63) | PDE3APDE4DSLC29A1POLA1ITGB3 | |
| SCHEMBL21849039 | 0.98 | PDE3A (0.63) | PDE3APDE4DSLC29A1POLA1ITGB3 | |
| SCHEMBL17770788 | 0.97 | PDE3A (0.62) | PDE3APDE4DSLC29A1POLA1ITGB3 | |
| SCHEMBL9798551 | 0.94 | PDE3A (0.66) | PDE3APDE4DSLC29A1POLA1ITGB3 | |
| SCHEMBL23724058 | 0.94 | PDE3A (0.66) | PDE3APDE4DSLC29A1POLA1ITGB3 | |
| SCHEMBL9798561 | 0.94 | PDE3A (0.66) | PDE3APDE4DSLC29A1POLA1ITGB3 | |
| SCHEMBL21849051 | 0.91 | PDE4D (0.63) | PDE3APDE4DSLC29A1POLA1ITGB3 | |
| SCHEMBL4931963 | 0.90 | PDE3A (0.62) | PDE3APDE4DSLC29A1POLA1ITGB3 | |
| SCHEMBL15197943 | 0.90 | PDE4D (0.62) | PDE3APDE4DSLC29A1POLA1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114585389-A | Therapeutic dendrimers | 星法马私人有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-7803785-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803785-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100016254-A1 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016254-A1 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-7608602-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608602-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080021208-A1 | Gemcitabine Prodrugs, Pharmaceutical Compositions and Uses Thereof | XENOPORT, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021208-A1 | Gemcitabine Prodrugs, Pharmaceutical Compositions and Uses Thereof | XENOPORT, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-7265096-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265096-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016254-A1 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TYMP, GDA, GCG | PDE3A 542/4885PDE4D 974/4885SLC29A1 41/4885 |
| US-20080021208-A1 | Gemcitabine Prodrugs, Pharmaceutical Compositions and Uses Thereof | TYMP, GDA, GCG | PDE3A 542/4885PDE4D 974/4885SLC29A1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.